Federated Hermes
ORIC icon

Federated Hermes’s Oric Pharmaceuticals ORIC Stock Holding History

Federated Hermes’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-152
Closed -$2.09K – 2107
2024
Q1 		$2.09K Buy
+152
New +$1.8K ﹤0.01% 1921
2023
Q4 		– Sell
-624
Closed -$3.77K – 2161
2023
Q3 		$3.77K Buy
624
+157
+34% +$1.29K ﹤0.01% 1913
2023
Q2 		$3.62K Buy
467
+324
+227% +$1.84K ﹤0.01% 1939
2023
Q1 		$815 Sell
143
-432
-75% -$2.26K ﹤0.01% 2053
2022
Q4 		$3.39K Buy
575
+141
+32% +$476 ﹤0.01% 1963
2022
Q3 		$1K Buy
+434
New +$1.74K ﹤0.01% 2068
2022
Q2 		– Sell
-506
Closed -$3K – 2243
2022
Q1 		$3K Buy
+506
New +$4.56K ﹤0.01% 2002

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes's ORIC Position: Q2 2024 in Review

Federated Hermes sold out of Oric Pharmaceuticals (ORIC) in Q2 2024, closing a stake of 152 shares — an estimated $2.09K sold.

Federated Hermes first reported a position in ORIC in Q1 2022 and held it in 7 quarters. The position peaked at $3.77K in Q3 2023. 113 funds tracked by Wall St. Rank hold ORIC as of Q2 2024.

  • Federated Hermes reported no remaining Oric Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Federated Hermes sold 152 Oric Pharmaceuticals shares in Q2 2024, an estimated $2.09K.
  • Federated Hermes first reported a position in Oric Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Federated Hermes's Oric Pharmaceuticals position peaked at $3.77K in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2024.

Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.